<DOC>
	<DOC>NCT00150436</DOC>
	<brief_summary>To evaluate long-term safety and efficacy of pregabalin in patients with postherpetic neuralgia.</brief_summary>
	<brief_title>To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia, Postherpetic</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Must have met the inclusion criteria for preceding doubleblind BID study in postherpetic neuralgia Must have received pregabalin/placebo under doubleblind conditions for a minimum of 3 weeks. Patients cannot participate if they experienced a serious adverse event during preceding doubleblind BID study which was determined to be related to the study medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>